On June 5, Henlius (2696.HK) participated in the 2025 Jefferies Global Healthcare Conference. As one of the most influential investment summits in the global life sciences industry, the event brought together over 3,000 leading executives, institutional investors, private equity investors and venture capitals to discuss current global trends and opportunities across the healthcare sector. Dr. Jason Zhu, CEO of Henlius, delivered a keynote speech presenting the company’s core strategy built on innovation, globalization, and patient centricity. He also shared key milestones in product pipeline development, frontier technology platforms, and manufacturing capacity expansion, showcasing the global value Henlius brings as a China-based biopharma company committed to innovation.
Driving Forward the Strategy of “Innovation for Global Access”
In his presentation, Dr. Zhu emphasized that Henlius remains deeply committed to addressing unmet medical needs worldwide by staying true to its patient-centered mission. To date, six products have been approved in China and four in ex-China markets, reaching more than 50 countries and regions and benefiting over 800,000 patients globally.
Henlius has built a diversified product portfolio spanning biosimilars, novel antibodies, antibody-drug conjugates (ADCs), and glycan editing therapeutics across oncology, autoimmune diseases, and ophthalmology. The company is focusing on prevalent global diseases such as breast cancer, lung cancer, and gastrointestinal tumors. At the recent 2025 ASCO Annual Meeting, Henlius released updated clinical results for three key innovative assets: serplulimab (anti-PD-1 mAb), HLX22 (anti-HER2 mAb), and HLX43 (PD-L1 ADC). These programs demonstrated encouraging efficacy and safety signals and are expected to offer breakthrough options for challenging cancers including lung and gastric cancers.
Building Sustainable Global Growth on a Solid Foundation
Dr. Zhu also highlighted Henlius’ progress in enhancing R&D and translational capabilities. The company has self-developed advanced platforms such as the rHuPH20-based hyaluronidase platform, the Hinova T-cell engager (TCE) platform, and the proprietary Hanjugator™ ADC platform, enabling integrated drug discovery, molecular design, and formulation development. These capabilities reflect Henlius’ continued investment in differentiated innovation and forward-looking research.
As the product pipeline and commercialization accelerate, Henlius continues to strengthen its global supply and industrial capabilities. The company currently operates 48,000L of commercial production capacity and has completed over 1,050 commercial GMP-certified manufacturing batches, ensuring stable supply across China, Southeast Asia, North America, Europe, the Middle East, and Latin America. Henlius is actively advancing the construction of its Songjiang Site II, which is expected to further strengthen its manufacturing capacity and expand into a broader range of product formats, including drug substance, liquid filling, pre-filled syringe, and ADC conjugation.
Henlius' quality system has undergone nearly 100 inspections and audits from global regulatory agencies and international partners. Its facilities and associated quality management systems have received GMP certifications from China, the EU, the U.S., and other PIC/S member countries (Brazil and Indonesia). These strengthened capabilities are not only enabling efficient pipeline advancement but also paving the way for global commercialization. They underscore Henlius’ steady progress and strategic commitment as a biopharma company dedicated to innovation and global growth.
Dr. Zhu noted that Henlius is accelerating toward shaping global impact by integrating end-to-end capabilities across R&D, manufacturing, regulatory, and commercialization, while deepening collaborations with global partners to benefit more patients worldwide. “Enduring biopharmaceutical companies don’t merely survive—they thrive through sustainable growth in a global system. At Henlius, we deliver more than medicine: we bring quality, technology, and trust to the world,” he said.
Looking ahead, Henlius will continue to advance guided by continuous innovation, a global development mindset, and a deep commitment to patient needs, firmly promoting the high-quality globalization of China’s biopharmaceutical industry.